Literature DB >> 15627897

Activation of activator protein 1 and extracellular signal-regulated kinases in human hepatocellular transformation.

Chien-Yun Hsiang1, Shih-Lu Wu, Tin-Yun Ho.   

Abstract

Hepatocellular carcinoma is one of the most common tumors worldwide. Activator protein 1 (AP-1) is a nuclear transcription factor, and its transactivation is required for transformation in several cell lines. However, no direct correlation between AP-1 activity and human hepatocellular transformation has been proved. Here we analyzed the role of AP-1 on the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced human hepatocellular transformation. TPA promoted the formation of anchorage-independent colonies, induced the AP-1 activity, and enhanced the DNA-binding ability of AP-1 in human hepatocytes. The phosphorylation of extracellular signal-regulated protein kinases (ERKs) was increased by TPA and the TPA-induced AP-1 activity was inhibited by PD98059, indicating that TPA-induced AP-1 activation was via ERK pathway. Moreover, retinoic acid and PD98059, which inhibited the AP-1 activity, abolished the TPA-induced transformation. Our findings indicated that AP-1 and ERKs activations were required for TPA-induced human hepatocellular transformation. These studies suggested that AP-1 could be the target for the development of antihepatocellular transformation agents. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627897     DOI: 10.1159/000081400

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  2 in total

1.  FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration.

Authors:  Gang Cen; Hong-Hua Ding; Bin Liu; Wei-Dong Wu
Journal:  Tumour Biol       Date:  2014-05-28

Review 2.  Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives.

Authors:  Xu Hu; Dahong Li; Chun Chu; Xu Li; Xianhua Wang; Ying Jia; Huiming Hua; Fanxing Xu
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.